ALGORITHM OF TREATMENT OF NON-ALCOHOLIC FATTY OF LIVER DISEASE AND THE ROLE OF MITOCHONDRIAL DYSFUNCTION IN ITS DEVELOPMENT


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The lack of a unified concept of the essence of the processes occurring in non-alcoholic fatty liver disease (NAFLD), scarcity of clinical symptoms, and the limited possibilities for timely diagnosis cause the interest of physicians of various specialties in seeking solutions to this problem. The issues related to the evaluation of etiopathogenesis, diagnosis, treatment and prevention of steatosis in patients with NAFLD still remain an urgent task for the world healthcare. Symptoms of mitochondrial dysfunction, such as changes in the lipidogram and lipid peroxidation indices, as well as in the hepatic cell during electron microscopy, arising from steatosis, confirm its role in the development and progression of the disease. This fact should be taken into account when drawing up a diagnosis plan and an algorithm for treating patients with NAFLD.

Full Text

Restricted Access

About the authors

V. G Radchenko

FSBEI HE “North-Western State Medical University n.a. I.I. Mechnikov"of RMH

St. Petersburg

P. V Seliverstov

FSBEI HE “North-Western State Medical University n.a. I.I. Mechnikov"of RMH

Email: seliverstov-pv@yandex.ru
PhD, Associate Professor at the Department of Internal Diseases and Nephrology St. Petersburg

V. F Ivanova

FSBEI HE “North-Western State Medical University n.a. I.I. Mechnikov"of RMH

St. Petersburg

S. I Sitkin

FSBEI HE “North-Western State Medical University n.a. I.I. Mechnikov"of RMH

St. Petersburg

References

  1. Лазебник Л.Б., Дуданова О.П., Радченко В.Г. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение. Экспериментальная и клиническая гастроэнтерология. 2015;119(7):85-96.
  2. Селиверстов П.В. Неалкогольная жировая болезнь печени: от теории к практике. Архив внутренней ме-дицины. 2015;1(21):19-26.
  3. Щекина М.И. Неалкогольная жировая болезнь печени. Consilium Medicum. 2009; 11(8):37-9.
  4. Angulo P., Lindor K.D. Non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2002;17(Suppl. 1):186-90.
  5. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summery of an AASLD Single Topic Con-ference. Hepatology. 2003;37:1202-19.
  6. Радченко В.Г., Шабров А.В., Зиновьева Е.Н., Ситкин С.И. Заболевания печени и желчевыводящих путей. СПб., 2011. 526 с.
  7. Павлов Ч.С., Ивашкин В.Т. Биопсия печени: методология и практика сегодня. Росс. журн. гастроэнтерол., гепатол., колопроктол. 2006;16(4):65-78.
  8. Павлов Ч.С., Золоторевский В.Б., Ивашкин В.Т. и др. Возможность обратимости цирроза печени (клинические и патогенетические предпосылки). Росс. журн. гастроэнтерол., гепатол, колопроктол. 2006;16(1):20-9.
  9. Brunt E.M. Non-alcoholic steatohepatiatis. Semin. Liver. Dis. 2004;24:3-20.
  10. Tandra S., Yeh M.M., Brunt E.M., Vuppalanchi R., Cummings O.W., Unalp-Arida A., Wilson L.A., Chalasani N. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J. Hepatol. 2011;55:654-59.
  11. Селиверстов П.В. Ожирение как фактор риска развития сердечно-сосудистых осложнений на фоне неалкогольной жировой болезни печени. Медицинский альманах. 2016;1(41):61-3.
  12. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., Angulo P. The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology. 2005;129:113-21.
  13. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysus nutrition and liver study. Hepatology. 2005;42:44-52.
  14. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005;115;1343-51.
  15. Niemela O., Parkkila S., Yla-Herttuala S., Villanueva J., Ruebner B., Halsted C.H. Sequential acetaldehyde pro-duction, lipid peroxidation and fibrogenesis in micro pig model of alcohol-induced liver disease. Hepatology. 1995;22:1208-14.
  16. Morino K., Petersen K.F., Shulman G.I. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006;55 (Suppl. 2): S9-S15.
  17. Park S.H. Nonalcoholic steatohepatitis: pathogenesis and treatment. Korean J. Hepatol. 2008;14(1):12-27.
  18. Santamaria E., Avila M.A., Latasa M.U., Rubio A., Martin-Duce A., Lu S.C., Mato J.M., Corrales F.J. Functional proteomics of nonalcoholic steatohepatitis: Mitochondrial proteins as targets of S-adenosylmethionine. Proc. Natl. Acad. Sci. USA. 2003;100(6):3065-70.
  19. Younossi Z.M. Review article: current management of nonalcoholic fatty liver disease and nonalcoholic steato-hepatitis. Aliment. Pharmacol. Ther. 2008;28(1):2-12.
  20. Mark N., de Alwis W., Day C.P. Current and future therapeutic strategies in NAFLD. Curr. Pharm. Des. 2010;16(17):1958-62.
  21. Medina J., Moreno-Otero R. Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs. 2005;65(17):2445-61.
  22. Chang C.Y., Argo C.K., Al-Osaimi A.M., Caldwell S.H. Therapy of NAFLD: Antioxidants and Cytoprotective Agents. J. Clin. Gastroenterol. 2006;40:S51-S60.
  23. Mehta K., Van Thiel D.H., Shah N., Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr. Rev. 2002;60(9):289-93.
  24. Musso G., Gambino R., Cassader M. Nonalcoholic fatty liver disease from pathogenesis to management: an up-date. Obes. Rev. 2010;11(6):430-45.
  25. Green D.R., Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305:626-29.
  26. Клембовский А.И., Сухоруков В.С. Учение о митохондриальной патологии в современной медицине. Материалы I Всероссийской конференции «Клинические и патогенетические проблемы нарушений клеточной энергетики». М., 1999. С. 28-30.
  27. Селиверстов П.В., Приходько Е., Радченко В., Орешко Л., Ситкин С., Адылов Ш., Юрькевич Ю., Супильникова О. Пути верификации неалкогольной жировой болезни печени. Врач. 2015;10:53-5.
  28. Стельмах В.В., Радченко В.Г., Козлов В.К. Метаболические корректоры на основе янтарной кислоты как средства патогенетической терапии при хронических вирусных гепатитах. Тер. архив. 2011;2:67-71.
  29. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
  30. Hickman I.J., Jonsson J.R., Prins J.B., Ash S., Purdie D.M., Clouston A.D., Powell E.E. Modest weight loss and physical activity in overweight patient with chronic liver disease result in suctaned improvements in alanine aminor ransferase, fasting insulin, and guality of life. Gut. 2004;53:413-19.
  31. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N., David E., Rizzetto M., Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcogolic fatti liver disease. Am. J. Gastroenterol. 2005;100(5):1082-90.
  32. Uygun A., Kadayifci A., Isik A.T., Ozgurtas T., Deveci S., Tuzun A., Yesilova Z., Gulsen M., Dagalp K. Metformin in the treatment of patients with non-alcoholic steatogepatitis. Phormacol. Ther. 2004;19(5):537-44.
  33. Augelico F., Burattin M., Alessandri C., Del Ben M., Lirussi F. Drugs improving insulin resistance for non - alcogolic fatti liver disease and/or njn alcogolic steatogepatitis. Cochrane Database Syst. Rev. 2007;1: CD005166.
  34. Флеркемайер В., Ситкин С.И. Холестатические заболевания печени: практическое руководство. М., 2016. 144 с.
  35. Радченко В.Г., Баскович Г.А., Стельмах В.В. Реамберин в комплексной терапии хронических гепатитов. Мир медицины. 2001; 9:19-20

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies